专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008124170A2 SELECTION OF HUMAN TNFα SPECIFIC ANTIBODIES 审中-公开
标题翻译：人TNFα特异性抗体的选择
公开(公告)号：WO2008124170A2
公开(公告)日：2008-10-16
申请号：PCT/US2008/004601
申请日：2008-04-10
申请人： VACCINEX, INC. , SMITH, Ernest, S. , CROY, Leslie, A. , SCRIVENS, Maria, G., M.
发明人： SMITH, Ernest, S. , CROY, Leslie, A. , SCRIVENS, Maria, G., M.
IPC分类号： C07K16/24 , C07K16/46 , A61K39/395 , C07H21/04 , A61K31/711 , C12N15/63 , C12N1/21 , C12P21/02 , A61P37/00
CPC分类号： C07K16/241 , C07K2317/24 , C07K2317/565 , C07K2317/92
摘要： The invention relates to antibodies which bind to tumor necrosis factor α (TNFα) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e.g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNFα - mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNFα to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e.g. rheumatoid arthritis (RA), using antibodies of the invention.
摘要翻译：本发明涉及结合肿瘤坏死因子α（TNFα）的抗体及其用途，特别是用于诊断和治疗自身免疫疾病，类风湿性关节炎（RA）。提供了抑制TNFα介导的信号传导途径的特异性人单克隆抗体及其变体，片段和衍生物。还提供了阻断TNFα结合其受体的能力的特异性人单克隆抗体，以及这些抗体的片段，变体和衍生物。本发明还包括编码上述抗体或其片段，变体或衍生物的多核苷酸，以及包含此类多核苷酸的载体和宿主细胞。本发明还包括诊断和治疗自身免疫疾病的方法，例如，类风湿性关节炎（RA），使用本发明的抗体。

2. 发明申请

WO2005055936A2 METHODS OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS 审中-公开
标题翻译：靶向抗凋亡肿瘤细胞的内部抗原杀伤肿瘤细胞的方法
公开(公告)号：WO2005055936A2
公开(公告)日：2005-06-23
申请号：PCT/US2004/040573
申请日：2004-12-06
申请人： VACCINEX, INC. , EVANS, Elizabeth E. , PARIS, Mark J. , SAHASRABUDHE, Deepak M. , SMITH, Ernest S. , ZAUDERER, Maurice
发明人： EVANS, Elizabeth E. , PARIS, Mark J. , SAHASRABUDHE, Deepak M. , SMITH, Ernest S. , ZAUDERER, Maurice
IPC分类号： A61K
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/73
摘要： The invention provides in vitro and in vivo methods of killing cancer cells, including therapeutic methods in humans, and also provides antibodies specific for the cancer specific antigen C35, and polynucleotides encoding such antibodies, as well as therapeutic and diagnostic methods of using such antibodies.
摘要翻译：本发明提供了杀伤癌细胞的体外和体内方法，包括人类中的治疗方法，并且还提供了对癌症特异性抗原C35特异性的抗体，以及编码这些抗体的多核苷酸以及治疗剂和使用这些抗体的诊断方法。

3. 发明申请

WO2004087058A3 TARGETED MHC CLASS I ALPHA3 VACCINE DELIVERY SYSTEMS 审中-公开
标题翻译：目标MHC类ALPHA3疫苗输送系统
公开(公告)号：WO2004087058A3
公开(公告)日：2005-06-02
申请号：PCT/US2004009385
申请日：2004-03-26
申请人： VACCINEX INC , ZAUDERER MAURICE , PARIS MARK J , SMITH ERNEST S
发明人： ZAUDERER MAURICE , PARIS MARK J , SMITH ERNEST S
IPC分类号： A61K20060101 , A61K38/00 , A61K39/00 , A61K39/145 , A61K39/25 , A61K39/38 , A61K39/40 , C07K14/045 , C07K14/74 , C07K16/28 , C07K16/46 , C12P21/08
CPC分类号： C07K14/005 , A61K38/00 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/605 , C07K14/70539 , C07K16/28 , C07K2319/00 , C12N2710/16122 , C12N2710/16134 , C12N2740/16134 , C12N2760/16134
摘要： The present invention is directed to a novel targeted vaccine delivery system, comprising one or more isolated MHC class I alpha3 domains linked to an antibody which is specific for a cell surface marker and associated with beta2-microglobulin and antigenic peptides, or costimulatory molecules, or cytokines. The complexes of the invention are useful for treating and/or preventing cancer, infectious diseases, autoimmune diseases, and/or allergies.
摘要翻译：本发明涉及一种新颖的靶向疫苗递送系统，其包含与抗体结合的一个或多个分离的MHC I型α3结构域，该抗体对细胞表面标记物特异性并与β2-微球蛋白和抗原肽或共刺激分子相关，或细胞因子。本发明的复合物可用于治疗和/或预防癌症，感染性疾病，自身免疫疾病和/或过敏。

4. 发明申请

WO2012031099A9 ANTI-CXCL13 ANTIBODIES AND METHODS OF USING THE SAME 审中-公开
公开(公告)号：WO2012031099A9
公开(公告)日：2012-03-08
申请号：PCT/US2011/050177
申请日：2011-09-01
申请人： VACCINEX, INC. , KLIMATCHEVA, Ekaterina , PARIS, Mark , SMITH, Ernest S.
发明人： KLIMATCHEVA, Ekaterina , PARIS, Mark , SMITH, Ernest S.
IPC分类号： C07K16/24
摘要： Compositions and methods are provided for treating diseases associated with CXCL13 expression, including certain autoimmune diseases, inflammatory diseases, and cancers. In particular, anti-CXCL13 monoclonal antibodies have been developed to neutralize CXCL13.

5. 发明申请

WO2008124170A3 SELECTION OF HUMAN TNFa SPECIFIC ANTIBODIES 审中-公开
标题翻译：选择人类TNFα特异性抗体
公开(公告)号：WO2008124170A3
公开(公告)日：2008-12-11
申请号：PCT/US2008004601
申请日：2008-04-10
申请人： VACCINEX INC , SMITH ERNEST S , CROY LESLIE A , SCRIVENS MARIA G M
发明人： SMITH ERNEST S , CROY LESLIE A , SCRIVENS MARIA G M
IPC分类号： C07K16/24
CPC分类号： C07K16/241 , C07K2317/24 , C07K2317/565 , C07K2317/92
摘要： The invention relates to antibodies which bind to tumor necrosis factor a (TNFa) and uses thereof, in particular in the diagnosis and treatment of autoimmune diseases, e.g. rheumatoid arthritis (RA). Specific human monoclonal antibodies which inhibit TNFa - mediated signalling pathways, and variants, fragments, and derivatives thereof are provided. Also provided are specific human monoclonal antibodies which block the ability of TNFa to bind to its receptor, as well as fragments, variants and derivatives of such antibodies. The invention also includes polynucleotides encoding the above antibodies or fragments, variants or derivatives thereof, as well as vectors and host cells comprising such polynucleotides. The invention further includes methods of diagnosing and treating autoimmune diseases, e.g. rheumatoid arthritis (RA), using antibodies of the invention.
摘要翻译：本发明涉及结合肿瘤坏死因子α（TNFa）的抗体及其用途，特别是在诊断和治疗自身免疫性疾病中的应用。类风湿关节炎（RA）。提供抑制TNFα介导的信号通路的特异性人单克隆抗体及其变体，片段及其衍生物。还提供阻断TNFα与其受体结合的能力的特异性人单克隆抗体，以及这些抗体的片段，变体和衍生物。本发明还包括编码上述抗体或其片段，变体或衍生物的多核苷酸，以及包含这种多核苷酸的载体和宿主细胞。本发明还包括诊断和治疗自身免疫疾病的方法，例如，类风湿性关节炎（RA），使用本发明的抗体。

6. 发明申请

WO2008063771A3 ANTI-CD20 ANTIBODIES AND METHODS OF USE 审中-公开
公开(公告)号：WO2008063771A3
公开(公告)日：2008-05-29
申请号：PCT/US2007/080925
申请日：2007-10-10
申请人： VACCINEX, INC. , SMITH, Ernest, S. , FISHER, Terrence, L., Jr.
发明人： SMITH, Ernest, S. , FISHER, Terrence, L., Jr.
IPC分类号： C07K16/28 , C12N5/06
摘要： Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.

7. 发明申请

WO2005055936A3 METHODS OF KILLING TUMOR CELLS BY TARGETING INTERNAL ANTIGENS EXPOSED ON APOPTOTIC TUMOR CELLS 审中-公开
标题翻译：通过靶向暴露于肿瘤细胞的内部抗原来杀死肿瘤细胞的方法
公开(公告)号：WO2005055936A3
公开(公告)日：2005-11-03
申请号：PCT/US2004040573
申请日：2004-12-06
申请人： VACCINEX INC , EVANS ELIZABETH E , PARIS MARK J , SAHASRABUDHE DEEPAK M , SMITH ERNEST S , ZAUDERER MAURICE
发明人： EVANS ELIZABETH E , PARIS MARK J , SAHASRABUDHE DEEPAK M , SMITH ERNEST S , ZAUDERER MAURICE
IPC分类号： A61K20060101 , A61K39/395 , C07H21/04 , C07K16/00 , C07K16/30 , C12N5/06 , G01N33/574
CPC分类号： C07K16/30 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/73
摘要： The invention provides in vitro and in vivo methods of killing cancer cells, including therapeutic methods in humans, and also provides antibodies specific for the cancer specific antigen C35, and polynucleotides encoding such antibodies, as well as therapeutic and diagnostic methods of using such antibodies.
摘要翻译：本发明提供了杀死癌细胞的体外和体内方法，包括在人体中的治疗方法，并且还提供了特异于癌症特异性抗原C35的抗体，以及编码这种抗体的多核苷酸以及使用这种抗体的治疗和诊断方法。

8. 发明申请

WO2004087058A2 TARGETED MHC CLASS I ALPHA3 VACCINE DELIVERY SYSTEMS 审中-公开
标题翻译：目标MHC类ALPHA3疫苗输送系统
公开(公告)号：WO2004087058A2
公开(公告)日：2004-10-14
申请号：PCT/US2004/009385
申请日：2004-03-26
申请人： ZAUDERER, Maurice , PARIS, Mark J. , SMITH, Ernest S.
发明人： ZAUDERER, Maurice , PARIS, Mark J. , SMITH, Ernest S.
IPC分类号： A61K
CPC分类号： C07K14/005 , A61K38/00 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/385 , A61K2039/57 , A61K2039/585 , A61K2039/605 , C07K14/70539 , C07K16/28 , C07K2319/00 , C12N2710/16122 , C12N2710/16134 , C12N2740/16134 , C12N2760/16134
摘要： The present invention is directed to a novel targeted vaccine delivery system, comprising one or more isolated MHC class I α3 domains linked to an antibody which is specific for a cell surface marker and associated with β2-microglobulin and antigenic peptides, or costimulatory molecules, or cytokines. The complexes of the invention are useful for treating and/or preventing cancer, infectious diseases, autoimmune diseases, and/or allergies.
摘要翻译：本发明涉及一种新颖的靶向疫苗递送系统，其包含与抗体结合的一个或多个分离的MHC I型α3结构域，该抗体对细胞表面标记物特异性并与β2-微球蛋白和抗原肽或共刺激分子相关，或细胞因子。本发明的复合物可用于治疗和/或预防癌症，感染性疾病，自身免疫疾病和/或过敏。

9. 发明申请

WO02086096A3 METHODS OF PRODUCING OR IDENTIFYING INTRABODIES IN EUKARYOTIC CELLS 审中-公开
标题翻译：在真核细胞中产生或鉴定入侵者的方法
公开(公告)号：WO02086096A3
公开(公告)日：2003-10-09
申请号：PCT/US0201677
申请日：2002-01-23
申请人： UNIV ROCHESTER MEDICAL CT , ZAUDERER MAURICE , WEI CHUNGWEN , SMITH ERNEST S
发明人： ZAUDERER MAURICE , WEI CHUNGWEN , SMITH ERNEST S
IPC分类号： C07K16/00 , C12P21/08 , C12Q1/70 , C12N15/00 , C12P21/06 , C12Q1/68
CPC分类号： C07K16/00 , C07K2317/21 , C12N2799/021 , C12N2799/022
摘要： The present invention relates to a high efficiency method of expressing intracellular immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing intracellular immunoglobulin libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for intracellular immunoglobulin molecules and fragments thereof. The invention also provides kits for producing, screening and selecting intracellular immunoglobulin molecules. Finally, the invention provides intracellular immunoglobulin molecules and fragments thereof, produced by the methods provided herein.
摘要翻译：本发明涉及在真核细胞中表达细胞内免疫球蛋白分子的高效方法。本发明进一步涉及生产细胞内免疫球蛋白文库的方法，特别是使用三分子重组方法在真核细胞中表达。本发明还提供了选择和筛选细胞内免疫球蛋白分子及其片段的方法。本发明还提供用于产生，筛选和选择细胞内免疫球蛋白分子的试剂盒。最后，本发明提供了通过本文提供的方法产生的细胞内免疫球蛋白分子及其片段。

10. 发明申请

WO2002102855A2 IN VITRO METHODS OF PRODUCING AND IDENTIFYING IMMUNOGLOBULIN MOLECULES IN EUKARYOTIC CELLS 审中-公开
标题翻译：生产和鉴定真核细胞中免疫球蛋白分子的体外方法
公开(公告)号：WO2002102855A2
公开(公告)日：2002-12-27
申请号：PCT/US2001/043076
申请日：2001-11-14
申请人： UNIVERSITY OF ROCHESTER , ZAUDERER, Maurice , SMITH, Ernest, S.
发明人： ZAUDERER, Maurice , SMITH, Ernest, S.
IPC分类号： C07K16/00
CPC分类号： C07K16/00 , C07K2317/21 , C07K2317/22 , C07K2317/55 , C07K2317/622 , C12N2799/023
摘要： The present invention relates to a high efficiency method of expressing immunoglobulin molecules in eukaryotic cells. The invention is further drawn to a method of producing immunoglobulin heavy and light chain libraries, particularly using the trimolecular recombination method, for expression in eukaryotic cells. The invention further provides methods of selecting and screening for antigen-specific immunoglobulin molecules, and antigen-specific fragments thereof. The invention also provides kits for producing, screening and selecting antigen-specific immunoglobulin molecules. Finally, the invention provides immunoglobulin molecules, and antigen-specific fragments thereof, produced by the methods provided herein.
摘要翻译：本发明涉及在真核细胞中表达免疫球蛋白分子的高效方法。本发明进一步涉及一种生产免疫球蛋白重链和轻链文库的方法，特别是使用三分子重组方法在真核细胞中表达。本发明还提供了选择和筛选抗原特异性免疫球蛋白分子及其抗原特异性片段的方法。本发明还提供用于产生，筛选和选择抗原特异性免疫球蛋白分子的试剂盒。最后，本发明提供了通过本文提供的方法产生的免疫球蛋白分子及其抗原特异性片段。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式